Predicting Therapeutic Results of Interferon Based Treatment by Modeling the First Week Viral Kinetics in Patients with Chronic Hepatitis C
نویسندگان
چکیده
Background: The present study aimed to develop an optimal model predictive of the treatment response one week after initiating antiviral therapy. Patients and Methods: In all, 166 patients completed the treatment and were followed up for six months. Results: A viral response was achieved in 14 (8.4%) genotype 1 (G1) and 32 (19.3%) non-genotype 1 (G0) patients at week one after initiation of therapy and 45 (27.1%) G1 and 90 (54.2%) G0 patients at week four. A sustained viral response (SVR) was achieved in 50 (30.1%) G1 and 83 (50.0%) G0 patients, in 13 (29.5%) G1 and 31 (70.5%) G0 patients whose antiviral response was achieved at one week, and in 37 G1 (32.2%) and 78 G0 (67.8%) patients whose antiviral response was achieved at four weeks. The HCV viral kinetic parameter π (i.e., 1: α, α was defined as the area under the line y [viral load]=– a[x{time}] between week 0 and week 1) was found to be the best performing test for predicting SVR (p<0.0001). Regression analysis identified π as the only independent predictor of SVR (p=0.043). Conclusions: The use of bio-mathematical models of HCV kinetics can reliably predict SVR one week after starting therapy.
منابع مشابه
Factors influencing therapeutic response to peginterferron plus ribavirin in the different genotypes of chronic hepatitis C
Abstract Background: Different factors like age, sex, route of infection, initial viral load, levels of liver function tests and genotypes may affect response to treatment in patients with chronic hepatitis C. The purpose of this study was to determine the role of these factors in the treatment of these patients. Methods: From 2004 to 2012, different genotypes of chronic HCV (Hepatitis C ...
متن کاملSAFETY AND EFFICACY OF INTERFERON ALFA FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED SUBJECTS WITH TRANSFUSION DEPENDENT THALASSEMIA IN IRAN
Up to 30% of Iranian adult multi-transfused thalassemic patients are infected with hepatitis C virus (HCV) which can intensify the progression of liver disease caused by iron overload in this group of patients. Our aim was to assess the biochemical and virological response of interferon alfa (INF-α) and its safety in thalassemic patients with chronic HCV infection. This trial was a single c...
متن کاملDetection of Pre-treatment mutations leading to resistance to direct hepatitis C virus blocking drugs in patients with chronic hepatitis C
Background and objective: Human is the only host of hepatitis C virus. This virus has a positive single stranded RNA and lipoprotein envelop that has 7 confirmed genotypes. According to studies, genotypes 1a, 3a and 1b are the most common genotypes in Iran. No effective vaccine against HCV infection has been developed instead, advances in antiviral treatment using drugs that directly affect spe...
متن کاملبررسی اثر آلفا انترفرون در 16 بیمار مبتلا به هپاتیت مزمن ویروسی
Alpha-interferon therapy has been approved for treatment of chronic hepatitis C and B. Candidates for treatment are patients with well-compensated liver disease and histologic evidences of chronic hepatitis who have demonstrated abnormal aminotransferase levels for more than 6 months. From 30 patients with chronic hepatitis with diseases prolonged more than 6 months, we selected only 16 patient...
متن کاملA MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HEBER ON (INTERFERON ALFA-2b) IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN IRAN
ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...
متن کامل